Organigram Posts 46% Revenue Growth and $20M Net Income in Q1
Organigram’s Q1 fiscal 2026 revenue rose 46% to $97.3 million while net income swung to $20.0 million from a $27.5 million loss, and adjusted EBITDA climbed 273% to $5.3 million. The company holds $63.0 million in cash and awaits EU-GMP certification to fuel further international growth.
1. Strong Q1 Financial Performance
For the quarter ended December 31, 2025, Organigram achieved gross revenue of $97.3 million, up 46% year over year, net revenue of $63.5 million, a 49% increase, net income of $20.0 million compared to a $27.5 million loss a year earlier, and adjusted EBITDA of $5.3 million, rising 273%.
2. Leadership Transition and Strategic Focus
James Yamanaka assumed the CEO role on January 15, 2026, highlighting Organigram’s competitive core business, innovation in plant science, operational efficiencies and disciplined execution as key drivers for sustained profitability. CFO Greg Guyatt noted elevated margins and forecasted continued revenue expansion driven by efficiency gains and product mix.
3. International Growth and EU-GMP Certification
Organigram is pursuing European Union Good Manufacturing Practice certification for its Moncton facility, having submitted responses to regulatory feedback in January 2026. Approval of EU-GMP status is seen as a critical milestone to access new markets and accelerate the company’s international expansion strategy.
4. Financial Position and Strategic Partnerships
As of December 31, 2025, Organigram reported cash and short-term investments of $63.0 million. The strategic partnership with British American Tobacco provides follow-on funding to support further international and U.S. market expansion initiatives.